Navigation Links
Vion Pharmaceuticals Holds Special Meeting of Stockholders
Date:2/13/2008

ith temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies or clinical trials are not predictive of safety and efficacy results in later clinical trials, the need for additional research and testing, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2006 and the Company's Form 10-Q for the quarter ended September 30, 2007. In particular, there can be no assurance as to the results of any of the Company's clinical trials, that any of these trials will continue to full accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to update arises under law when prior disclosure becomes materially misleading in light of sub
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... December 22, 2014 The Center ... leader of technical training across the life sciences industry, ... Management (SCDM) to provide the organization's members with ... —providing access to the more than 350 sessions across ... with 10% off when registering for a public ...
(Date:12/22/2014)... 22, 2014  Alternative Energy & Environmental Solutions, ... signed a letter of intent to acquire BioTechPharma ... patented a nanotechnology-based development platform used to create ... rapid on-site collection and testing to identify infectious ... in an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3ALNE Announces Intention To Acquire BioTechPharma 2
... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), a specialty ... full year 2010 on Thursday, February 10, 2011 before the ... conduct a conference call that day at 10:00 a.m. ET ... full year 2010.  The presentation slides to be used during ...
... Biotechnology and Biomedicine and the UAB Department of Biochemistry ... using Saccharomyces cerevisiae yeast to detect in ... of molecules which can initiate the assembly of amyloid ... the efficacy of compounds which could dissolve or inhibit ...
... Calif., Feb. 2, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... 2010 financial results and accomplishments. For the ... net loss of $8.3 million, or $0.18 per share, compared ... share, for the same period in 2009. As of December ...
Cached Biology Technology:Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 2Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 3Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 4New test to study proteins involved in neurodegenerative diseases 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... common form of lung cancer may begin in a group ... the Howard Hughes Medical Institute. , Working in a mouse ... that can divide into fresh copies of itself and into ... lung. Their experiments show that at the earliest stage of ...
... suggests that medications commonly referred to as fertility drugs ... called the estrogen receptor beta. The study showed that ... that were genetically engineered to lack estrogen receptor beta. ... receptor proteins which mediate the effects of estrogen hormones ...
... In the human brain, cells talk to one another ... people fall into a deep sleep, the higher regions ... are a bustling grid of neural dialogue - apparently ... fade. , Writing today (Sept. 30) in the journal ...
Cached Biology News:Most common lung cancers may begin in newly discovered cells 2Most common lung cancers may begin in newly discovered cells 3Most common lung cancers may begin in newly discovered cells 4New Discovery May Help Doctors Treat Infertility 2New Discovery May Help Doctors Treat Infertility 3Deep sleep short-circuits brain's grid of connectivity 2Deep sleep short-circuits brain's grid of connectivity 3
Anti-Human Complement Component C4c, IgY fraction (Polyclonal) (chicken IgY)...
... test tubes are used to store 2.0 ... have uniform walls for uniform heat transfer ... screw caps. The O-rings are made of ... range from -55 to 150 degrees C. ...
... Affi-Prep protein A media yield highly ... prior to analysis of other immunoglobulin ... antigen purification. Protein A binds to ... IgG from mammalian species. This ready-to-use, ...
... bis- (3-D-Gluconamidopropyl)deoxycholamide White solid. HYGROSCOPIC. ... CHAPSO. Has reduced electrostatic interactions that do ... DEAE-cellulose. Aggregation number: 8-16. Purity: ≥95% ... O. Aggregation number 8 - 16, CMC ...
Biology Products: